U.S. Exchanges
list of publicly traded healthcare companies cancer
Comprehensive directory of oncology market leaders and biotech innovators developing next-generation ADC, CAR-T, and immunotherapy cancer treatments for 2026.
This page is for informational and educational purposes only and does
not constitute investment advice. Always consult a qualified financial
professional before making investment decisions.
Navigating the list of publicly traded healthcare companies cancer is critical for investors seeking exposure to the most innovative segment of the complete healthcare directory. As of April 2026, the oncology market is being redefined by antibody-drug conjugates (ADCs) and bispecific antibodies, which are showing clinical success rates nearly triple those of traditional chemotherapy. While large-cap giants anchor the sector with stable revenues, many investors look to mid-cap cancer companies for a balance of proven assets and high-growth potential. For those with a higher risk tolerance, tracking breakthrough assets within small-cap cancer research can offer significant upside ahead of pivotal Phase 3 readouts. This guide provides a structured look at the firms leading the fight against cancer across major U.S. stock exchanges.
Key Takeaways
01
ADC Market Surge
Antibody-drug conjugates are projected to hit $15B in peak sales by 2030, with Gilead and AstraZeneca leading the approved category. This technology is a primary driver for biotech companies overview analysis.
02
Immunotherapy Dominance
Regeneron and Merck continue to dominate the PD-1/immuno-oncology landscape, focusing on combination therapies to overcome treatment resistance in solid tumors.
03
Trial Success Shifts
Next-gen modalities like bispecifics are seeing success rates of 35-45%, a massive improvement over the historical oncology trial average of 10-15%.
04
Radiopharma Expansion
Targeted radiopharmaceuticals are emerging as a $5B market opportunity, providing a specialized vertical for investors alongside traditional cancer diagnostics leaders.
Top list of publicly traded healthcare companies cancer by Market Cap (2026)
The following table highlights the market leaders in oncology development, tracking valuation alongside lead assets and anticipated 2026 clinical catalysts.
| Rank | Ticker | Company | Modality | Market Cap | Lead Asset | Phase | 2026 Catalyst |
|---|---|---|---|---|---|---|---|
| 1 | AZN | AstraZeneca | ADC/IO | $220B | Enhertu | Approved | Q3 Expansion Data |
| 2 | REGN | Regeneron | IO/Bispecific | $120B | Libtayo | Approved | Q3 Combo Readout |
| 3 | GILD | Gilead Sciences | ADC/CAR-T | $95B | Trodelvy | Approved | New Indication PDUFA |
| 4 | MRK | Merck & Co. | Immunotherapy | $320B | Keytruda | Approved | Sasanlimab PDUFA |
| 5 | INCY | Incyte Corp | Small Molecule | $14B | Opzelura | Expansion | Phase 3 Readout |
| 6 | EXEL | Exelixis | TKI/ADC | $8B | Cabometyx | Approved | ADC Pipeline Entry |
| 7 | BMRN | BioMarin | Rare Oncology | $16B | Pipeline | Phase 2/3 | Clinical Data H2 |
| 8 | AMGN | Amgen | Bispecific | $150B | Blincyto | Approved | Myeloma Readout |
| 9 | NVS | Novartis | Radiopharma | $210B | Pluvicto | Approved | Label Expansion |
| 10 | BMY | Bristol Myers | IO/CAR-T | $105B | Opdivo | Approved | Combo Approvals |
Market data is approximate and for informational purposes only. Data reflects early Q2 2026 figures. Not a recommendation to buy or sell.
list of publicly traded healthcare companies cancer — Complete Company List
Cancer Focused Companies
A list of publicly traded cancer companies can be found by scrolling down or you can access a list of the companies in each group through the industry links on this page.
- Becton, Dickinson and Company (BDX)
- Celgene Corporation (CELG)
- Regeneron Pharmaceuticals, Inc. (REGN)
Industry Links: Cancer
- Mid-Cap Cancer Research and Treatment Companies
- Small-Cap Cancer Research and Treatment Companies
- Micro-Cap Cancer Research and Treatment Companies
- Nano-Cap Cancer Research and Treatment Companies
Cancer: IPOs in 2016
- Aeglea BioTherapeutics, Inc. (AGLE) (IPO April 7, 2016: Biotech company focused on therapeutics for the treatment of inborn errors of metabolism (IEM)
- Beigene, Ltd. (BGNE) (IPO February 3, 2016: Biopharmaceutical company with therapeutics designed to treat cancer)
- Corvus Pharmaceuticals, Inc. (CRVS) (IPO March 23, 2016: Biopharmaceutical company focused on immuno-oncology therapies for cancer)
- Hutchison China MediTech Limited (HCM) (IPO March 17, 2016: Biopharmaceutical company focused on immunological diseases and oncology in addition to consumer health products)
- Kadmon Holdings, Inc. (KDMN) (IPO July 27, 2016: biopharmaceutical company developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases)
- Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)
- Moleculin Biotech, Inc. (MBRX) (IPO June 2, 2016: clinical stage pharmaceutical company, anticancer drug candidates)
- Sensus Healthcare, Inc. (SRTSU) (IPO June 3, 2016: medical device company focused on skin cancers as well as other skin conditions)
- Syndax Pharmaceuticals, Inc. (SNDX) (IPO March 3, 2016: Biopharmaceutical company engaged in the development of cancer treatments)
- Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: Biopharmaceutical company, gene control medicines)
Cancer: Comparison Widgets
- Cancer Diagnostic Industry Comparison Widget
- Mid-Cap Cancer Industry Comparison Widget
- Small-Cap Cancer Industry Comparison Widget
- Micro-Cap Cancer Industry Comparison Widget
- Nano-Cap Cancer Industry Comparison Widget
Diagnostics
- Biocept, Inc. (BIOC) (Molecular oncology diagnostics)
- Cancer Genetics, Inc. (CGIX) (DNA-based diagnostics)
- Check-Cap Ltd. (CHEK) (IPO in January 2015, Israel: Ingestible imaging capsule for the screening for colorectal cancer)
- EXACT Sciences Corporation (EXAS) (Molecular diagnostics)
- Genetic Technologies Ltd. (GENE) (Molecular diagnostics: cancer management tests)
- Genomic Health, Inc. (GHDX) (Molecular diagnostics)
- Invitae Corporation (NVTA) (Genetic diagnostics for hereditary disorders)
- ITUS Corporation (ITUS) (Diagnostics)
- Myriad Genetics, Inc. (MYGN) (Hereditary cancer, nephrology, autoimmune diseases, diabetes, neuropsychiatry)
- Navidea Biopharmaceuticals, Inc. (NAVB) (Precision diagnostics, therapeutics and radiopharmaceutical agents)
- OncoCyte Corporation (OCX) (Liquid biopsy cancer diagnostic tests)
- VolitionRX Limited (VNRX) (Singapore: diagnostic tests for cancer and other diseases)
Cancer: Mid-Cap Stocks
- Exelixis, Inc. (EXEL) (Biopharmaceutical company: small molecule therapies used in the treatment of cancer)
- Ionis Pharmaceuticals, Inc. (IONS) (RNA-targeted drug discovery and development: cancer, cardiovascular, metabolic, neurological disorders, rare diseases)
- PerkinElmer, Inc. (PKI) (Electronic laboratory notebook and software, neonatal and newborn screening, cancer treatment, environmental)
- Seattle Genetics, Inc. (SGEN) (Antibody-based therapies for the treatment of cancer)
- Varian Medical Systems, Inc. (VAR) (Oncology treatment systems and software, X-ray products)
Cancer: Small-Cap Stocks
- Acceleron Pharma Inc. (XLRN) (Cancer and orphan diseases)
- Adaptimmune Theapeutics plc (ADAP) (United Kingdom, biopharmaceutical company: cancer immunotherapy products)
- Aduro BioTech, Inc. (ADRO) (IPO in April 2015: Cancer immunotherapy; pancreatic cancer)
- Advaxis, Inc. (ADXS) (Clinical-stage biotechnology company: immunotherapies to treat cancer)
- Agenus Inc. (AGEN) (Immunology: cancer, infectious diseases)
- Agios Pharmaceuticals, Inc. (AGIO) (Biopharmaceutical company: cancer and rare genetic disorders of metabolism)
- AngioDynamics, Inc. (ANGO) (Medical devices used treatment of cancer and peripheral vascular disease)
- Arcus Biosciences, Inc. (RCUS) (IPO March 15, 2018; biopharmaceutical company: cancer immunotherapies)
- argenx SE (ARGX) (IPO May 18, 2017; biotech company: autoimmune diseases and cancer)
- ARMO BioSciences, Inc. (ARMO) (IPO January 26, 2018; immuno-oncology company)
- Ariad Pharmaceuticals, Inc. (ARIA) (Oncology company: chronic and acute leukemia, lung cancer and other difficult-to-treat cancers)
- Array BioPharma Inc. (ARRY) (Biopharmaceutical company: targeted small molecule drugs used to treat patients afflicted with cancer)
- Atara Biotherapeutics, Inc. (ATRA) (Molecularly-targeted product candidates and T-cell product candidates; cancer, kidney disease and other illnesses)
- Athenex, Inc. (ANTX) (IPO June 14, 2017; biopharmaceutical company: cancer)
- Beigene, Ltd. (BGNE) (IPO February 3, 2016: Biopharmaceutical company with therapeutics designed to treat cancer)
- Bellicum Pharmaceuticals, Inc. (BLCM) (Biopharmaceutical company: cellular immunotherapies for various forms of cancer; hematological and solid tumors, orphan inherited blood disorders)
- BeyondSpring Inc. (BYSI) (IPO March 9, 2017; cancer therapies)
- Blueprint Medicines Corporation (BPMC) (IPO in April 2015: Biopharmaceutical company: kinase inhibitors for genomically defined cancers)
- Cellectis SA (CLLS) (IPO in March 2015, France: Gene-editing company; cancer therapies based on engineered T cells)
- Celldex Therapeutics, Inc. (CLDX) (Therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines; brain cancer, triple negative breast cancer)
- Clovis Oncology, Inc. (CLVS) (Biopharmaceutical company: cancer treatments; non-small cell lung cancer, ovarian cancer, pancreatic cancer, breast and lung cancers)
- Compugen Ltd. (CGEN) (Israel: immuno-oncology programs which are aimed at harnessing the immune system to eradicate cancer)
- Concordia Healthcare Corp. (CSRX) (Canada: ADHD, cancer and asthma)
- Cue Biopharma, Inc. (CUE) (IPO January 2, 2018; biopharmaceutical company: cancer and autoimmune disorders)
- CytomX Therapeutics Inc. (CTMX) (IPO in October 2015: Biopharmaceutical company; antibody therapeutics, oncology)
- Deciphera Pharmaceuticals, Inc. (DCPH) (IPO September 28, 2017; biopharmaceutical company: cancer)
- Eagle Pharmaceuticals, Inc. (EGRX) (Injectable products: critical care and oncology)
- Epizyme, Inc. (EPZM) (Biopharmaceutical company: therapeutics for patients with genetically defined cancers)
- ERYTECH Pharma S.A. (ERYP) (IPO November 10, 2017; France: biopharmaceutical company: cancer)
- FibroGen, Inc. (FGEN) (Biopharmaceutical company: anemia in chronic kidney disease, liver fibrosis, pancreatic cancer, corneal blindness)
- G1 Therapeutics, Inc. (GTHX) (IPO May 17, 2017; biopharmaceutical company: cancer)
- Geron Corporation (GERN) (Biopharmaceutical company: telomerase inhibitor in hematologic myeloid malignancies)
- Halozyme Therapeutics, Inc. (HALO) (Oncology therapies that target the tumor microenvironment)
- Heron Therapeutics, Inc. (HRTX) (Pharmaceutical products for patients suffering from cancer or pain)
- Hutchison China MediTech Limited (HCM) (IPO March 17, 2016: Biopharmaceutical company focused on immunological diseases and oncology in addition to consumer health products)
- ICU Medical, Inc. (ICUI) (Products used in critical care applications, oncology and vascular therapy)
- Immunomedics, Inc. (IMMU) (Biopharmaceutical company: antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases)
- Inovio Pharmaceuticals, Inc. (INO) (Cancer, infectious diseases, vaccines)
- Iovance Biotherapeutics, Inc. (IOVA) (Immunotherapies based on tumor infiltrating lymphocytes)
- Jounce Therapeutics, Inc. (JNCE) (IPO January 27, 2017; cancer immunotherapies)
- Kadmon Holdings, Inc. (KDMN) (IPO July 27, 2016: biopharmaceutical company developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases)
- Karyopharm Therapeutics Inc. (KPTI) (Drugs for the treatment of cancer and other major diseases)
- Loxo Oncology, Inc. (LOXO) (Cancer therapies)
- MacroGenics, Inc. (MGNX) (Biopharmaceutical company: monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases)
- Merrimack Pharmaceuticals, Inc. (MACK) (Biopharmaceutical company: cancer)
- Mersana Therapeutics, Inc. (MRSN) (IPO June 28, 2017; biopharmaceutical company: cancer)
- Mesoblast Ltd. (MESO) (IPO in November 2015, Australia: regenerative medicine company; areas of focus include inflammation, cardiovascular disease and back pain)
- Mirati Therapeutics, Inc. (MRTX) (Oncology company: genetically-targeted oncology therapeutics)
- Momenta Pharmaceuticals, Inc. (MNTA) (Therapeutics for oncology and autoimmune indications)
- Nantkwest Inc. (NK) (IPO in June 2015: Immunotherapy company: cancer)
- NewLink Genetics Corporation (NLNK) (Biopharmaceutical company: immunotherapy products, pancreatic cancer)
- NovoCure Ltd. (NVCR) (IPO in October 2015, oncology company: treatment of solid tumor cancers)
- NuCana plc (NCNA) (IPO September 28, 2017; biopharmaceutical company: medicines designed to overcome key cancer resistance mechanisms using proprietary ProTide technology)
- Odonate Therapeutics, Inc. (ODT) (IPO December 7, 2017; pharmaceutical company: cancer)
- OncoMed Pharmaceuticals, Inc. (OMED) (Biopharmaceutical company: antibody therapeutics targeting cancer stem cells)
- Progenics Pharmaceuticals Inc. (PGNX) (Oncology company: diagnostic and therapeutic needs of prostate cancer patients)
- Puma Biotechnology Inc. (PBYI) (Biopharmaceutical company: products for the treatment of various forms of cancer)
- Regulus Therapeutics Inc. (RGLS) (Biopharmaceutical company: microRNA therapeutics for oncology indications and orphan diseases)
- Spectrum Pharmaceuticals, Inc. (SPPI) (Hematology, oncology)
- Tesaro, Inc. (TSRO) (Biopharmaceutical company: oncology therapeutics and supportive care products)
- TG Therapeutics, Inc. (TGTX) (Biopharmaceutical company: B-cell malignancies and autoimmune diseases)
- Unum Therapeutics Inc. (UMRX) (IPO March 29, 2018; biopharmaceutical company: immunotherapy products)
- Xbiotech Inc. (XBIT) (Biopharmaceutical company: cancer antibodies)
- Zai Lab Limited (ZLAB) (IPO September 20, 2017; biopharmaceutical company: autoimmune diseases, cancer, infectious diseases)
- Ziopharm Oncology Inc. (ZIOP) (Biopharmaceutical company: cell-based therapies for the treatment of cancer)
- Zymeworks Inc. (ZYME)
Cancer: Micro-Cap Stocks
- Actinium Pharmaceuticals, Inc. (ATNM) (Biopharmaceutical company: immunotherapeutics for the treatment of advanced cancers)
- Affimed N.V. (AFMD) (Germany, biopharmaceutical company: cancer immunotherapies)
- Aileron Therapeutics, Inc. (ALRN) (IPO June 29, 2017; biopharmaceutical company: cancer)
- Anavex Life Sciences Corp. (AVXL) (Biopharmaceutical company: Alzheimer’s, other CNS diseases; cancer)
- ArQule, Inc. (ARQL) (Small molecule cancer therapeutics)
- AVEO Pharmaceuticals, Inc. (AVEO) (Biopharmaceutical company: therapies through biomarker-driven insights)
- Bio-Path Holdings, Inc. (BPTH) (Therapeutic products utilizing its proprietary liposomal delivery technology; blood cancer, triple negative and inflammatory breast cancers)
- BioXcel Therapeutics, Inc. (BTAI) (IPO March 8, 2018; biopharmaceutical company: neuroscience and immuno-oncology)
- CASI Pharmaceuticals, Inc. (CASI) (Biopharmaceutical company: therapeutics addressing cancer and other unmet medical needs; focus on China)
- Celcuity Inc. (CELC) (IPO September 20, 2017; diagnostic tests for new cancer subtypes)
- Cellular Biomedicine Group, Inc. (CBMG) (Treatments for degenerative and cancerous diseases)
- Cel-Sci Corporation (CVM) (Immunotherapy products for the treatment of cancer and infectious diseases)
- Celyad SA (CYAD) (IPO in June 2015: Cell therapy treatments; cardiovascular disease, oncology)
- ChemoCentryx, Inc. (CCXI) (Biopharmaceutical company: orally-administered therapeutics for the treatment of autoimmune diseases, inflammatory disorders and cancer)
- Concert Pharmaceuticals, Inc. (CNCE) (CNS disorders, renal disease, inflammation and cancer)
- CTI BioPharma Corp. (CTIC) (Biopharmaceutical company: therapies covering a spectrum of blood-related cancers)
- Curis, Inc. (CRIS) (Drug candidates for the treatment of human cancers)
- Dicerna Pharmaceuticals, Inc. (DRNA) (Biopharmaceutical company: inherited diseases of the liver and genetically defined cancers)
- Endocyte, Inc. (ECYT) (Biopharmaceutical company: therapies for the treatment of cancer and inflammatory diseases)
- ESSA Pharma Inc. (EPIX) (Canada: small molecule drugs for the treatment of prostate cancer)
- Fate Therapeutics, Inc. (FATE) (Biopharmaceutical company: cellular immunotherapeutics; cancer, rare genetic diseases and immune disorders)
- Fortress Biotech (FBIO) (Biopharmaceutical company: cancer, additional products in pipeline)
- Genprex, Inc. (GNPX) (IPO March 29, 2018; gene therapy: cancer)
- GTX, Inc. (GTXI) (Small molecules for the treatment of cancer and serious medical conditions)
- Immune Design Corp. (IMDZ) (Immunotherapy company)
- ImmunoGen, Inc. (IMGN) (Tumor-targeting antibodies to deliver a cell-killing agent specifically to cancer cells)
- Immutep Limited (IMMP) (Immunotherapeutic products for the treatment of cancer)
- Infinity Pharmaceuticals, Inc. (INFI) (Biopharmaceutical company: Blood cancers, indolent non-Hodgkin lymphoma, chronic lymphocytic leukemia)
- Kura Oncology, Inc. (KURA) (IPO in November 2015: Biopharmaceutical company; therapeutics for the treatment of solid tumors and blood cancers)
- Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)
- Midatech Pharma plc (MTP) (Oncology treatment and supportive care products)
- Moleculin Biotech, Inc. (MBRX) (Clinical stage pharmaceutical company, anticancer drug candidates)
- Northwest Biotherapeutics, Inc. (NWBO) (Cancer vaccines designed to treat a broad range of solid tumor cancers)
- Oasmia Pharmaceutical AB (OASM) (IPO in October 2015, Sweden: Human and animal oncology)
- Oncobiologics, Inc. (ONS) (IPO May 13, 2016, biopharmaceutical company: biosimilar therapeutics)
- Pieris Pharmaceuticals, Inc. (PIRS) (Biotechnology company: areas of focus include cancer, asthma and anemia)
- PTC Therapeutics, Inc. (PTCT) (Biopharmaceutical company: oral treatments)
- Rexahn Pharmaceuticals, Inc. (RNN) (Biopharmaceutical company: therapeutics for the treatment of cancer)
- Rigel Pharmaceuticals, Inc. (RIGL) (Small-molecule drugs for the treatment of immune diseases and cancers)
- SELLAS Life Sciences Group, Inc. (SLS) (Biopharmaceutical company: cancer immunotherapies)
- Sensus Healthcare, Inc. (SRTS) (IPO June 3, 2016: medical device company focused on skin cancers as well as other skin conditions)
- Sesen Bio, Inc. (SESN) (Antibody-drug conjugate (ADC)
- Sierra Oncology, Inc. (SRRA) (Oncology company)
- Sorrento Therapeutics, Inc. (SRNE) (Oncology company: treatments for cancer and associated pain)
- Stemline Therapeutics, Inc. (STML) (Biopharmaceutical company: therapeutics that target cancer stem cells and tumor bulk)
- Syndax Pharmaceuticals, Inc. (SNDX) (IPO March 3, 2016: Biopharmaceutical company engaged in the development of cancer treatments)
- Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: Biopharmaceutical company, gene control medicines)
- Tocagen Inc. (TOCA) (IPO April 13, 2017; cancer-selective gene therapies)
- Tracon Pharmaceuticals, Inc. (TCON) (IPO in January 2015: Biopharmaceutical company: therapeutics for cancer, age-related macular degeneration and fibrotic diseases)
- Trillium Therapeutics Inc. (TRIL) (Canada: immuno-oncology company)
- Vascular Biogenics Ltd. (VBLT) (Israel: Treatments for cancer)
- Verastem, Inc. (VSTM) (Biopharmaceutical company: drugs to treat cancer by the targeted killing of cancer stem cells)
- VTV Therapeutics Inc. (VTVT) (IPO in July 2015: Clinical stage pharmaceutical company: cancer, central nervous system disorders, diabetes and metabolic disorders, inflammation)
Cancer: Nano-Cap Stocks
- Aethlon Medical, Inc. (AMED) (Diagnostics and therapeutic devices: cancer and infectious diseases)
- American Shared Hospital Services (AMS) (Radiosurgical devices and radiosurgery equipment)
- Aptose Biosciences, Inc. (APTO) (Canada: therapeutics to treat life-threatening cancers; acute myeloid leukemia, high-risk myelodysplastic syndromes)
- Can-Fite Biopharma Ltd (CANF) (Israel: biopharmaceutical company: autoimmune-inflammatory and cancer diseases)
- Cellectar Biosciences, Inc. (CLRB) (Agents to detect, treat and monitor a broad spectrum of cancers)
- Celsion Corporation (CLSN) (Oncology company: chemotherapies, immunotherapies and RNA- or DNA-based therapies)
- Champions Oncology, Inc. (CSBR) (Solutions and services designed to personalize the development and use of oncology drugs)
- Cleveland BioLabs, Inc. (CBLI) (Biopharmaceutical company: toll-like immune receptor activators; applications in radiation mitigation, oncology immunotherapy and vaccines)
- Cyclacel Pharmaceuticals, Inc. (CYCC) (Biopharmaceutical company: oral therapies used in the treatment of cancer and other serious diseases)
- CytRx Corporation (CYTR) (Biopharmaceutical company: research and development company specializing in oncology)
- Galectin Therapeutics Inc. (GALT) (Therapies for fibrotic diseases and cancer)
- Heat Biologics, Inc. (HTBX) (Therapeutic vaccines to combat a wide range of cancers and infectious diseases)
- Immune Pharmaceuticals Inc. (IMNP) (Antibody therapeutics: inflammatory diseases and cancer)
- ImmunoCellular Therapeutics, Ltd. (IMUC) (Immune-based therapies for the treatment of brain cancers and other cancers)
- Kazia Therapeutics (KZIA) (Biotech company: oncology)
- MEI Pharma, Inc. (MEIP) (Therapies for the treatment of cancer)
- Onconova Therapeutics, Inc. (ONTX) (Biopharmaceutical company: small molecule drug candidates used in the treatment of cancer)
- OncoSec Medical Inc. (ONCS) (Technologies designed to stimulate the body’s immune system; cancer)
- Sunesis Pharmaceuticals, Inc. (SNSS) (Biopharmaceutical company: oncology therapeutics for the potential treatment of solid and hematologic cancers)
- TetraLogic Pharmaceuticals Corporation (TLOG) (Biopharmaceutical company: cancer and infectious diseases)
- XTL Biopharmaceuticals Ltd. (XTLB) (Israel, biopharmaceutical company: autoimmune diseases; blood cancer)
- Zymeworks Inc. (ZYME) (IPO April 28, 2017; biopharmaceutical company: cancer)
Risks & Considerations
Clinical Trial Failure
Even with improved success rates for ADCs, a negative Phase 3 readout can wipe out 50% or more of a small or mid-cap company's valuation in a single trading session.
FDA Regulatory Uncertainty
Meeting primary endpoints does not guarantee approval; the FDA may require additional safety data or survival benefit evidence, delaying commercialization by years.
Cash Runway Constraints
Early-stage oncology biotechs often burn hundreds of millions annually; companies with less than 12 months of cash runway face extreme dilution risk from secondary offerings.
Exclusivity and Patent Cliffs
Large-cap cancer leaders face looming biosimilar competition for blockbuster drugs, necessitating constant pipeline renewal through expensive M&A activity.
These risk factors are for educational purposes only and are not exhaustive. Individual investment decisions should be based on thorough due diligence.
Frequently Asked Questions
Regeneron (REGN) leads at $120B with Libtayo/PD-1 dominance, followed by Gilead (GILD) at $95B (Trodelvy ADC) and AstraZeneca (AZN) at $220B (Enhertu). Smaller pure-plays like Exelixis (EXEL) maintain significant valuations on their flagship assets.
The 2026 PDUFA calendar features Merck (MRK) for sasanlimab, Bristol Myers (BMY) for Opdivo combinations, and Gilead (GILD) for additional Trodelvy indications. Bispecifics from Amgen and Roche are also targeting key 2026 readouts.
Gilead, AstraZeneca, and Pfizer (via Seagen) lead the approved ADC category. $15B in peak sales is projected for top ADCs by 2030, with Merck and BMS advancing next-gen payloads.
Incyte offers a strong cash position, while Exelixis generates nearly $2B in annual revenue from Cabometyx. BioMarin is also advancing rare cancer assets with managed cash burn.
ADC and bispecific tailwinds currently favor mid and large-caps with proven clinical platforms. Trial success rates are rising, though CAR-T expansion into solid tumors remains a high-risk area.
The SPDR S&P Biotech (XBI) is roughly 45% oncology weighted, while the iShares Nasdaq Biotech (IBB) offers 38% cancer exposure. ARK Genomic (ARKG) focuses on early-stage immuno-oncology.
Gilead and BMS/J&J dominate the approved CAR-T space with significant 2025 sales. Allogene is a notable name advancing "off-the-shelf" CAR-T for solid tumors.
Radiopharma (e.g., Novartis Pluvicto) delivers localized radiation directly to cancer cells. It is currently a fast-growing market, specifically targeting PSMA+ prostate cancer.
Last updated April 2026 · Data sourced from U.S. exchange filings
